Keyword: Tremfya (guselkumab)
Sun Pharma debuts its first TV ad for psoriasis treatment Ilumya as national TV campaigns become table stakes in the crowded psoriasis category.
Johnson & Johnson’s Tremfya put a key rival on defense late last year with head-to-head data, and it’s keeping the heat on its competitors.
Competition and discounting are unsurprisingly taking a toll on J&J’s older drugs. But cardiovascular product Xarelto is also on that list.
Johnson & Johnson knows the immunology market is crowded. But that doesn’t mean it doesn’t still see tons of opportunity there.
Johnson & Johnson’s Tremfya may have debuted behind Novartis' Cosentyx, but it has now topped the blockbuster in a head-to-head trial.
Johnson & Johnson immunology newcomer Tremfya is looking to follow in the footsteps of its big brother Stelara.
Johnson & Johnson, the perennial top dog in FiercePharma's annual report profiling leading drug companies, grabbed the No. 1 spot once again.
Sun Pharma’s $80 million psoriasis licensing deal just paid off. But now, its new drug Ilumya will go up against established player J&J.
After a bruising two-day play-in, Taltz and Nerlyx are among the victors in our first round of this year’s drug name tournament challenge.
Tremfya, the next-gen psoriasis biologic from Johnson & Johnson, began airing its first DTC campaign two weeks ago, joining two close rivals on the tube.